LYKALABSBSELYKA LABS LTD.· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 10 Aug, 2026 · 12:24 IST

Lyka Labs Q1 loss Rs 30 cr standalone, to divest Lyka BDR subsidiary

Revenue DeclinePat NegativeExceptional ItemResults RestatedResults View source PDFExplain this filing

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+2.0%Reaction day
₹66.75
prior close
₹67.10
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+2.0% vs market
Pharmaceuticals peers, median of 165sector-0.1%+2.1% vs sector

On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+2.0-0.1+2.0-0.1+2.1
Next day
+1.5-0.2+1.7+0.0+1.4
2d
+0.0+0.1-0.1-0.1+0.1
3d
+1.9+0.3+1.6+0.2+1.7
4d
-0.1+0.4-0.5-0.6+0.6
5d
+1.9+0.5+1.4-1.2+3.1
1w
+6.0+0.3+5.7-2.0+8.0
15d
+12.9+1.9+11.0+0.1+12.8
1m
+26.1+2.2+24.0+1.4+24.8
2m
+9.1-1.2+10.3-2.0+11.2
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lyka Labs posted Q1 FY27 standalone net loss of Rs 29.77 cr versus profit of Rs 2.10 cr a year ago. Revenue fell sharply to Rs 28.54 cr from Rs 124.88 cr, hurt by exceptional items of Rs 29.90 cr. Consolidated net loss was Rs 8.07 cr. Board approved 100 percent divestment of subsidiary Lyka BDR International, which has negative net worth of Rs 4.49 cr. Results are restated after merger of Lyka Export into the company. Auditor gave an unqualified review report.

Likely market impact

Weak quarter with steep revenue fall and large loss; divesting loss-making subsidiary may help streamline operations ahead.